This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-16 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The second concern would be that some of the heavy metals that could be released can have some level of toxicity to not only organisms inhabiting that area but also organisms passing through the mining site area. The concerns surrounding increased sediment release are mainly related to the other two mining waste processes, side cast sediment and seafloor sediment disturbance. The main environmental concern would be the smothering of organisms below as a result of redistributing large amounts of sediment to other areas on the seafloor, which could potentially threaten the population of organisms inhabiting the area. Redistribution of large quantities of sediment can also affect the feeding and gas exchange processes between organisms, posing a serious threat to the population. Finally, these processes can also increase the sedimentation rate on the seafloor, resulting in a predicted minimum of 500 m per every 1–10 km. A large amount of work is currently being engaged in by both of the above-mentioned companies to ensure that the potential environmental impacts of seafloor mining are well understood and control measures are implemented before exploitation commences. However, this process has been arguably hindered by the disproportionate distribution of research effort among vent ecosystems; the best studied and understood hydrothermal vent ecosystems are not representative of those targeted for mining. Attempts have been made in the past to exploit minerals from the seafloor.
As of the 2020 census, there were 467,665 people, 188,412 households, and 104,848 families residing in the city. In the American Community Survey of 2019, the city of Raleigh's population was estimated at 474,708; an earlier estimate determined the population at 474,069. At the 2000 census, there were 276,093 persons (July 2008 estimate was 380,173) and 61,371 families residing in Raleigh. The population density was 2,409.2 people per square mile (930.2 people/km2). There were 120,699 housing units at an average density of 1,053.2 per square mile (406.6/km2). There were 112,608 households in the city in 2000, of which 26.5% included children below the age of 18, 39.5% were composed of married couples living together, 11.4% reported a female householder with no husband present, and 45.5% classified themselves as nonfamily. Unmarried partners were present in 2.2% of households. In addition, 33.1% of all households were composed of individuals living alone, of which 6.2% was someone 65 years of age or older. The average household size in Raleigh was 2.30 persons, and the average family size was 2.97 persons. Raleigh's population in 2000 was evenly distributed with 20.9% below the age of 18, 15.9% aged 18 to 24, 36.6% from 25 to 44, and 18.4% from 45 to 64. An estimated 8.3% of the population was 65 years of age or older, and the median age was 31 years. For every 100 females, there were 98.0 males; for every 100 females aged 18 or older, there were 96.6 males aged 18 or older.
Which plants have which types of defense? Which herbivores, specifically, are the plants defended against? What chemical structures and mechanisms of toxicity are involved in the compounds that provide defense? What are the potential medical uses of these compounds? These questions and others constitute an active area of research in modern botany, with important implications for understanding plant evolution and medical science. Below is an extensive, if incomplete, list of plants containing one or more poisonous parts that pose a serious risk of illness, injury, or death to humans or domestic animals. There is significant overlap between plants considered poisonous and those with psychotropic properties, some of which are toxic enough to present serious health risks at recreational doses. There is a distinction between plants that are poisonous because they naturally produce dangerous phytochemicals, and those that may become dangerous for other reasons, including but not limited to infection by bacterial, viral, or fungal parasites; the uptake of toxic compounds through contaminated soil or groundwater; and/or the ordinary processes of decay after the plant has died; this list deals exclusively with plants that produce phytochemicals. Many plants, such as peanuts, produce compounds that are only dangerous to people who have developed an allergic reaction to them, and with a few exceptions, those plants are not included here (see list of allergens instead).
== Multiple valves == Multiple check valves can be connected in series. For example, a double check valve is often used as a backflow prevention device to keep potentially contaminated water from siphoning back into municipal water supply lines. There are also double ball check valves in which there are two ball/seat combinations sequentially in the same body to ensure positive leak-tight shutoff when blocking reverse flow; and piston check valves, wafer check valves, and ball-and-cone check valves.
Sources: en.wikipedia.org
=== Mechanism of action === Phentolamine acts as a reversible dual or non-selective α1- and α2-adrenergic receptor antagonist. Its primary action is vasodilation due to α1-adrenergic receptor blockade. Reportedly, phentolamine may also stimulate β-adrenergic receptors. Non-selective α-blockers can cause a much more pronounced reflex tachycardia than the selective α1 blockers. Like the selective α1 blockers, phentolamine causes a relaxation of systemic vasculature, leading to hypotension. This hypotension is sensed by the baroreceptor reflex, which results in increased sympathetic nerve firing on the heart, releasing norepinephrine. In response, the β1 adrenergic receptors on the heart increase their rate, contractility, and dromotropy, which help to offset the decrease in systemic blood pressure. Unlike the α1 selective blockers, phentolamine also inhibits the α2 receptors, which function predominantly as presynaptic negative feedback for norepinephrine release. By abolishing this negative feedback phentolamine leads to even less regulated norepinephrine release, which results in a more drastic increase in heart rate.
Determining the location in space of a given blip was a complex multi-step process. First the operator would select a set of receiver antennas using the motorized switch, feeding signals to the receiver system. The antennas were connected together in pairs, forming two directional antennas, sensitive primarily along the X and Y axes respectively, Y being the line of shoot. The operator would then "swing the gonio", or "hunt", back and forth until the selected blip reached its minimum deflection on this display (or maximum, at 90 degrees off). The operator would measure the distance against the scale, and then tell the plotter the range and bearing of the selected target. The operator would then select a different blip on the display and repeat the process. For targets at different altitudes, the operator might have to try different antennas to maximize the signal. On the receipt of a set of polar coordinates from the radar operator, the plotter's task was to convert these to X and Y locations on a map. They were provided with large maps of their operational area printed on lightweight paper so they could be stored for future reference. A rotating straightedge with the centrepoint at the radar's location on the map was fixed on top, so when the operator called an angle the plotter would rotate the straightedge to that angle, look along it to pick off the range, and plot a point. The range called from the operator is the line-of-sight range, or slant range, not the over-ground distance from the station.
Improved Benevolent and Protective Order of Elks Independent Benevolent and Protective Order of Moose Independent Order of Good Samaritans and Daughters of Samaria - Founded September 14, 1847, as a temperance order in New York City by I. W. B. Smith. It was an authorized branch of the white Grand United Order of Good Samaritans which had been founded that March. Had initiated over 400,000 members by 1897. It was described as having educational as well as mutual benefit aspects including sickness, death, disability, and old age benefits. In 1897 the Order had lodges in every US state and England. Its logo was a dove and olive branch enclosed in a triangle with the words Love, Purity, and Truth emblazoned on them. This symbolized perfection, equality, and the trinity. The Orders headquarters were in Washington, DC. Improved Order of the Shepherds and Daughters of Bethlehem - Founded in 1910 in Richmond, Virginia. Independent Order of Immaculates of the United States of America - Founded June 23, 1872, in Nashville, Tennessee, by W. A. Hadley. Evolved from Young Men's Immaculate Association but was different in that it was patterned after secret fraternal orders and that it admitted men and women. Had about 5,000 members in 1897. Headquartered in Nashville. Independent Order of Saint Luke - Based in Richmond, Virginia. Had 49,498 members at the end of 1921. Attempts to reach it in 1923 were unsuccessful.
Sources: en.wikipedia.org
The United States Department of Agriculture (USDA) considers GMOs to be plants or animals with heritable changes introduced by genetic engineering or traditional methods, while GEO specifically refers to organisms with genes introduced, eliminated, or rearranged using molecular biology, particularly recombinant DNA techniques, such as transgenesis. The definitions focus on the process more than the product, which means there could be GMOS and non-GMOs with very similar genotypes and phenotypes. This has led scientists to label it as a scientifically meaningless category, saying that it is impossible to group all the different types of GMOs under one common definition. It has also caused issues for organic institutions and groups looking to ban GMOs. It also poses problems as new processes are developed. The current definitions came in before genome editing became popular and there is some confusion as to whether they are GMOs. The EU has adjudged that they are changing their GMO definition to include "organisms obtained by mutagenesis", but has excluded those "obtained by means of certain mutagenesis techniques, namely those which have conventionally been used in a number of applications and have a long safety record" from regulation. This refers to traditional random mutagenesis (radiation/chemical mutation breeding) and would not exclude "new techniques" (especially those that have emerged since the adoption of the GMO directive) like gene editing. In contrast the USDA has ruled that gene edited organisms are not considered GMOs.
Diabetic hypoglycemia is a low blood glucose level occurring in a person with diabetes mellitus. It is one of the most common types of hypoglycemia seen in emergency departments and hospitals. According to the National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP), and based on a sample examined between 2004 and 2005, an estimated 55,819 cases (8.0% of total admissions) involved insulin, and severe hypoglycemia is likely the single most common event. In general, hypoglycemia occurs when a treatment to lower the elevated blood glucose of diabetes inaccurately matches the body's physiological need, and therefore causes the glucose to fall to a below-normal level.
Eastern Theater Command Southern Theater Command Western Theater Command Northern Theater Command Central Theater Command The service headquarters retain operational control in some areas within China and outside of China. For example, army headquarters controls or is responsible for the Beijing Garrison, the Tibet Military District, the Xinjiang Military District, and border and coastal defences. The counterpiracy patrols in the Gulf of Aden are controlled by navy headquarters. The JSD nominally controls operations beyond China's periphery, but in practice this seems to apply only to army operations. Services and theater commands have the same grade. The overlap of areas or units of responsibility may create disputes requiring CMC arbitration. As part of the 2015 reforms, military regions were replaced by theatre commands in 2016. Military regions were − uinlike the theatre commands − army-centric peacetime administrative organizations, and joint wartime commands were created on-demand by the army-dominated General Staff Department.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.